GlassScriptPhysician profile
David A Montgomery
NPI 1538151139
$1,622.08
in general payments reported to CMS, 2019-2025
24 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $256 · 2021: $205 · 2022: $196 · 2023: $146 · 2024: $276 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $621.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $278.71 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $202.47 | 2019-2024 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $185.65 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $135.68 | 2019-2024 | Airsupra |
| Pfizer INC. | $111.11 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $91.08 | 2020-2023 | Xarelto |
| Amarin Pharma, INC. | $67.98 | 2019-2021 | |
| Abbvie INC. | $63.04 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $53.49 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $51.15 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.27 | 2019-2022 | |
| Corcept Therapeutics | $48.49 | 2025 | Korlym |
| Astellas Pharma US INC | $45.31 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $42.28 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $37.02 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $33.63 | 2022-2023 | Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $23.38 | 2024 | Rexulti |
| Mayne Pharma Commercial LLC | $16.90 | 2020 | |
| Insulet Corporation | $15.82 | 2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $15.37 | 2022 | |
| Boston Scientific Corporation | $14.05 | 2025 | Watchman Access System |
| Dexcom, INC. | $13.54 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $13.12 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.